Recent Finacing
Recent Raise
Genascence is a Palo Alto–based gene therapy company developing an AAV-delivered interleukin-1 receptor antagonist (IL‑1Ra) for single-injection, long-term intra-articular inhibition of IL‑1 to treat osteoarthritis.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Genascence.
